期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 131, 期 3, 页码 -出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI144893
关键词
-
资金
- NIH [2P01 NS092521, F30 HL140871, R01 HL056687, HL075443, R01 HL075443, T32 GM007171]
- American Heart Association [18PRE34060061]
- Fondation Leducq [17 CVD 03]
- Be Brave for Life
Propranolol, a pleiotropic beta-adrenergic blocker, has shown promising results in reducing cerebral cavernous malformations in animal models such as zebrafish and mice, possibly due to its beta 1 adrenergic antagonism. These findings suggest that propranolol or other beta 1-selective antagonists may be beneficial in treating CCM disease.
Propranolol, a pleiotropic beta-adrenergic blocker, has been anecdotally reported to reduce cerebral cavernous malformations (CCMs) in humans. However, propranolol has not been rigorously evaluated in animal models, nor has its mechanism of action in CCM been defined. We report that propranolol or its S(-) enantiomer dramatically reduced embryonic venous cavernomas in ccm2 mosaic zebrafish, whereas R-(+)-propranolol, lacking beta antagonism, had no effect. Silencing of the beta 1 but not beta 2, adrenergic receptor mimicked the beneficial effects of propranolol in a zebrafish CCM model, as did the beta 1-selective antagonist metoprolol. Thus, propranolol ameliorated cavernous malformations by beta 1 adrenergic antagonism in zebrafish. Oral propranolol significantly reduced lesion burden in 2 chronic murine models of the exceptionally aggressive Pdcd/Ccm3 form of CCM. Propranolol or other beta 1-selective antagonists may be beneficial in CCM disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据